Compare Stocks: CRBP, ENTX, PROK, and ARVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.41 -0.3%	$8.65	$6.97 ▼ $14.51	$478.09M	1.8	831,143 shs	585,121 shs
CRBP Corbus Pharmaceuticals	$6.13 -3.3%	$9.24	$6.06 ▼ $20.56	$114.45M	2.63	466,188 shs	834,833 shs
ENTX Entera Bio	$2.86 -1.0%	$2.96	$0.91 ▼ $4.20	$497.41M	1.4	1.02 million shs	100,699 shs
PROK ProKidney	$1.72 +0.6%	$1.68	$1.30 ▼ $3.48	$519.99M	1.77	1.11 million shs	1.09 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-4.01%	-4.62%	-19.94%	-11.44%	-18.62%
CRBP Corbus Pharmaceuticals	-7.04%	-14.90%	-43.79%	-31.46%	-51.38%
ENTX Entera Bio	-0.69%	+3.21%	-0.34%	+74.10%	+54.55%
PROK ProKidney	+3.01%	+1.79%	-7.57%	-15.76%	-34.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.41 -0.3%	$8.65	$6.97 ▼ $14.51	$478.09M	1.8	831,143 shs	585,121 shs
CRBP Corbus Pharmaceuticals	$6.13 -3.3%	$9.24	$6.06 ▼ $20.56	$114.45M	2.63	466,188 shs	834,833 shs
ENTX Entera Bio	$2.86 -1.0%	$2.96	$0.91 ▼ $4.20	$497.41M	1.4	1.02 million shs	100,699 shs
PROK ProKidney	$1.72 +0.6%	$1.68	$1.30 ▼ $3.48	$519.99M	1.77	1.11 million shs	1.09 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-4.01%	-4.62%	-19.94%	-11.44%	-18.62%
CRBP Corbus Pharmaceuticals	-7.04%	-14.90%	-43.79%	-31.46%	-51.38%
ENTX Entera Bio	-0.69%	+3.21%	-0.34%	+74.10%	+54.55%
PROK ProKidney	+3.01%	+1.79%	-7.57%	-15.76%	-34.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.30	Hold	$14.55	96.72% Upside
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	563.86% Upside
ENTX Entera Bio	2.83	Moderate Buy	$9.60	233.33% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	612.17% Upside

Current Analyst Ratings Breakdown

Latest CRBP, ENTX, PROK, and ARVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2026	ENTX Entera Bio	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
9/22/2026	ENTX Entera Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
9/18/2026	ENTX Entera Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$9.00
9/18/2026	ENTX Entera Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
9/14/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
9/3/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/26/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$262.60M	1.82	N/A	N/A	$6.76 per share	1.09
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
ENTX Entera Bio	$40K	12,522.24	N/A	N/A	$0.29 per share	9.93
PROK ProKidney	$890K	572.37	N/A	N/A	($3.36) per share	-0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	73.91	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	11/11/2026 (Estimated)
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)

Latest CRBP, ENTX, PROK, and ARVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
ENTX Entera Bio	N/A	8.98	8.98
PROK ProKidney	N/A	8.36	8.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
CRBP Corbus Pharmaceuticals	64.64%
ENTX Entera Bio	14.11%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
CRBP Corbus Pharmaceuticals	3.50%
ENTX Entera Bio	10.57%
PROK ProKidney	39.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	246	64.52 million	59.81 million	Optionable
CRBP Corbus Pharmaceuticals	36	18.67 million	18.02 million	Optionable
ENTX Entera Bio	21	173.92 million	155.54 million	Optionable
PROK ProKidney	231	302.32 million	181.91 million	Optionable

CRBP, ENTX, PROK, and ARVN Headlines

Recent News About These Companies

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

3 hours ago | markets.businessinsider.com

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

October 2 at 9:00 AM | globenewswire.com

ProKidney consensus price target increased by 22.40% to MX$116.87

September 29 at 7:56 PM | msn.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell?

September 21, 2026 | marketbeat.com

ProKidney (PROK) Stock Forecast & Price Target

September 19, 2026 | investing.com

ProKidney (NASDAQ:PROK) Trading 6% Higher - Still a Buy?

September 16, 2026 | marketbeat.com

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

September 11, 2026 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Stock Price Up 7.6% - Should You Buy?

September 4, 2026 | marketbeat.com

ProKidney Corp. (PROK) Options Chain - Yahoo Finance

August 26, 2026 | finance.yahoo.com

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

August 14, 2026 | seekingalpha.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Gets a Buy from Guggenheim

August 12, 2026 | theglobeandmail.com

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2026 | zacks.com

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

August 10, 2026 | manilatimes.netM

ProKidney Cell Therapy Thwarts Onerous Dialysis

July 30, 2026 | bloomberg.com

ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance

July 14, 2026 | finance.yahoo.com

ProKidney Corp (NASDAQ: PROK) - Share Price and Research

July 13, 2026 | intelligentinvestor.com.auI

What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?

July 9, 2026 | kalkinemedia.comK

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

June 17, 2026 | insidermonkey.com

ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout

June 2, 2026 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, ENTX, PROK, and ARVN Company Descriptions

Arvinas NASDAQ:ARVN

$7.41 -0.02 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$7.42 +0.00 (+0.07%)

As of 04:44 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Corbus Pharmaceuticals NASDAQ:CRBP

$6.13 -0.21 (-3.31%)

Closing price 04:00 PM Eastern

Extended Trading

$6.28 +0.15 (+2.45%)

As of 04:31 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Entera Bio NASDAQ:ENTX

$2.86 -0.03 (-1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 +0.02 (+0.66%)

As of 05:02 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ProKidney NASDAQ:PROK

$1.72 +0.01 (+0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 +0.01 (+0.81%)

As of 04:42 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, ENTX, PROK, and ARVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, ENTX, PROK, and ARVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, ENTX, PROK, and ARVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, ENTX, PROK, and ARVN Company Descriptions

Arvinas NASDAQ:ARVN

Corbus Pharmaceuticals NASDAQ:CRBP

Entera Bio NASDAQ:ENTX

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, ENTX, PROK, and ARVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, ENTX, PROK, and ARVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, ENTX, PROK, and ARVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, ENTX, PROK, and ARVN Company Descriptions

Arvinas NASDAQ:ARVN

Corbus Pharmaceuticals NASDAQ:CRBP

Entera Bio NASDAQ:ENTX

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools